In addition, the identification of CD47 and CD133 levels as prognostic factors could be incorporated into standard clinical prognostic considerations across multiple subtypes of lung cancer and may be useful in risk-adapted therapy decision-making. This evidence concerns the gene CD47 and lung cancer.